Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Conditions

Breast Neoplasms 13138 Neoplasms 10481 Carcinoma, Non-Small-Cell Lung 6874 Prostatic Neoplasms 6268 Colorectal Neoplasms 5948 Lung Neoplasms 5105 Multiple Myeloma 3577 Pancreatic Neoplasms 3563 Leukemia, Myeloid, Acute 3510 Neoplasm Metastasis 3508 Carcinoma, Hepatocellular 3273 Ovarian Neoplasms 3168 Melanoma 3141 Stomach Neoplasms 3057 Lymphoma 2983 Head and Neck Neoplasms 2604 Recurrence 2557 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2499 Leukemia 2362 Colonic Neoplasms 2328 Brain Neoplasms 2313 Lymphoma, Non-Hodgkin 2269 Rectal Neoplasms 2192 Uterine Cervical Neoplasms 2191 Glioblastoma 2016 Leukemia, Lymphocytic, Chronic, B-Cell 1992 Carcinoma, Renal Cell 1913 Squamous Cell Carcinoma of Head and Neck 1880 Lymphoma, Follicular 1848 Esophageal Neoplasms 1801

Interventions

pembrolizumab 1 Nivolumab 1 Immune Checkpoint Inhibitors 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Efficacy, Team × Clear all

NCT06693440 2024-11-18

The Immune Assessment of PD-1 Antibody Therapy in Tumor

Henan Cancer Hospital

Efficacy, Team

Data powered by HemOnc (CC BY 4.0) Colophon ⚡